XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
  IBS
  Liver
  GERD
  Constipation
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Nov 17th, 2006 - 22:35:04

Gastroenterology Channel
subscribe to Gastroenterology newsletter

Latest Research : Gastroenterology

   DISCUSS   |   EMAIL   |   PRINT
FDA Approves I V Esomeprazole magnesium for Short-term Treatment of Gastroesophageal Reflux Disease
Apr 2, 2005, 08:50, Reviewed by: Dr.

"Hospitalized patients with GERD are often unable to take their oral medication. The availability of NEXIUM in an intravenous formulation provides these patients with an effective alternative route of administration that they can tolerate easily."

 
AstraZeneca (NYSE: AZN - News) today announced that a new administration formulation for its prescription proton pump inhibitor NEXIUM� (esomeprazole magnesium) has been approved by the US Food and Drug Administration (FDA). NEXIUM I.V. is now approved as an intravenous infusion or injection for the short-term treatment (up to 10 days) of gastroesophageal reflux disease (GERD) patients, with a history of erosive esophagitis, who are unable to take capsules.

NEXIUM� I.V. (esomeprazole sodium) for injection is administered once daily as either a 10 to 30 minute intravenous infusion or by intravenous injection (no less than 3 minutes). Treatment is given for up to 10 days and does not require an in-line filter.

"Hospitalized patients with GERD are often unable to take their oral medication," said David C. Metz, M.D., Professor of Medicine in the Division of Gastroenterology at the Hospital of the University of Pennsylvania. "The availability of NEXIUM in an intravenous formulation provides these patients with an effective alternative route of administration that they can tolerate easily."

"AstraZeneca is pleased to be able to make this new intravenous formulation of NEXIUM available to healthcare professionals," said Mark Sostek, MD, Senior Medical Director for AstraZeneca. "We are dedicated to providing healthcare professionals and the patients they treat with innovative treatment options."

The approval of NEXIUM I.V. was based, in part, on the findings of four multicenter, open-label, two-period crossover studies. These studies compared the pharmacodynamic efficacy of the intravenous formulation with NEXIUM delayed-release capsules at corresponding doses of 20 mg and 40 mg in GERD patients with or without a history of erosive esophagitis. They demonstrated that, after 10 days of once-daily administration, NEXIUM I.V. 20 mg and 40 mg are similar in their ability to suppress acid to the corresponding oral dosage form of NEXIUM. There were no relevant changes in acid suppression when switching between intravenous and oral dosage form.

NEXIUM oral is indicated for treating frequent, persistent heartburn and other symptoms associated with acid reflux disease. The drug was recently approved for reducing the risk of gastric (stomach) ulcers developing among at risk patients on continuous NSAID therapy. It also is approved for healing erosive esophagitis. Most erosions heal in 4 to 8 weeks. Individual results may vary, and only a doctor can determine if erosions to the esophagus have occurred. Symptom relief does not rule out the existence of other serious stomach conditions.

The most common side effects of NEXIUM are headache, diarrhea and abdominal pain. For full prescribing information for NEXIUM please visitthe related link.
 

- U.S. Food and Drug Administration (FDA)
 

AstraZeneca

 
Subscribe to Gastroenterology Newsletter
E-mail Address:

 

AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world's leading pharmaceutical companies with healthcare sales of over $21.4 billion and leading positions in sales of gastrointestinal, cardiovascular, respiratory, oncology and neuroscience products. In the United States, AstraZeneca is a $9.6 billion healthcare business with more than 12,000 employees. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index.For more information about AstraZeneca, please visit the Company's website.

Related Gastroenterology News

British scientists create artificial stomach
Researchers find a gene variant that protects against development of IBD
MR Elastography may help in early diagnosis of liver fibrosis
Lactose intolerance does not mean total avoidance of dairy foods
Why does prolonged IV feeding damage the liver?
Oral enzyme therapy for celiac sprue may mean less dietary restrictions
Coffee may reduce risk of alcoholic cirrhosis
Benefits of Polyflex Esophageal Stents For Treating Refractory Benign Esophageal Strictures
Novel visualization by SpyGlass System may reduce repeat ERCP procedures
Endoscopic clips useful in patients on coumadin anticoagulation therapy undergoing colonoscopy


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us